Cross-topic event
Novartis pelacarsen: ~78% Lp(a) drop, but HORIZON CV outcomes stay neutral (cardiovascular)
Nov 7, 20262 reports
Nov 7, 2026
Sciencedesk view
Novartis pelacarsen: ~78% Lp(a) drop, but HORIZON CV outcomes stay neutral (cardiovascular)
At AHA Scientific Sessions with simultaneous NEJM publication, the Phase 3 Lp(a) HORIZON trial in ~8,322 adults with established CVD and baseline Lp(a) ≥70 mg/d…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
AHA 2026 / NEJM: pelacarsen sharply lowers Lp(a) but does not cut secondary-prevention MACE (Public health / Lipids)
The phase 3 Lp(a)HORIZON double-blind RCT enrolled 8,323 adults with established cardiovascular disease and Lp(a) ≥70 mg/dL across 797 sites in 42 countries, ra…
READ THE DAY'S DIGEST →